Main Menu

Ebola virus infection can lead to severe hemorrhagic fever, known as Ebola virus disease (EVD), which is often fatal. The Zaire species of Ebola virus (EBOV) was responsible for the largest Ebola outbreak in history, which occurred in 2014. Scientists at the NIAID Vaccine Research Center have developed a human monoclonal neutralizing antibody, mAb114 for treatment and prevention of EBOV infection. Because there are very few treatments available to treat or prevent EBOV infection, there is a great need to develop effective pre- and post- exposure therapeutics before another outbreak occurs.

Influenza B causes significant morbidity and mortality yearly around the world. There are two genetically and antigenically distinct lineages of influenza B that are known to co-circulate within the same influenza season. Currently, the trivalent influenza vaccine only has one influenza B lineage component.

Anti-neoplastic drugs, also known as anti-cancer drugs or chemotherapy, are used in the treatment of many types of cancer. However, these drugs are harmful to healthy cells as well as the cancerous cells. Exposure of healthcare workers to anti-neoplastic drugs from contaminated surfaces and drug vials in hospitals and pharmacies is a continuing problem as the drugs can cause both acute and long-term effects. Although there are sensitive techniques to evaluate contamination, results from these tests take time and must be performed in a laboratory.

HIV and AIDS remain persistent problems for the United States and countries around the world. In 2015, nearly 40,000 people were diagnosed with HIV in the US alone. Pre-exposure prophylaxis (PrEP) can help prevent HIV infections in people who are not infected with HIV but are at high risk of becoming infected with HIV. PrEP involves taking daily medications and is the most effective when medications are taken consistently. However, many people find it challenging to adhere to a daily pill schedule and cannot fully benefit from PrEP.

As of March 2017, 64 countries and territories had travel notices for active Zika virus transmissions. CDC developed the Trioplex rRT-PCR test to detect evidence of Zika virus infection and aid in differentiating this infection from dengue and chikungunya virus infections, all of which are spread by the same types of Aedes species mosquitoes and cause similar illness.

The 2014-2016 Ebola Virus Disease (EVD) outbreak in West Africa was the largest in history, causing more than 28,000 suspected, probable, and confirmed infections and more than 11,000 deaths across nine countries. CDC scientists designed nucleic acid primers and probes which can be used in a sensitive test for detecting all known strains of Ebola virus (species Zaire ebolavirus) including the 2014/2015 strain that emerged in West Africa and the more recent strain that caused an EVD outbreak in the Democratic Republic of Congo in 2017.

Zika virus (ZIKV) is a flavivirus primarily transmitted by infected Aedes mosquitoes. Infection with ZIKV during pregnancy can affect the fetus causing microcephaly, neurological complications, and other birth defects. Adults are also at a heightened risk of developing Guillain-Barre syndrome and other neurological disorders. In response to the 2015-2016 Zika outbreak, CDC scientists developed a recombinant vaccine candidate as well as reagents and methods to detect ZIKV infection. The recombinant vaccine candidate utilizes adenovirus vector expressed viral envelope proteins.

Inhibiting the ability of HIV-1, the virus that causes AIDS, to infect cells is one approach to both prevention and treatment of HIV. Scientists at the NIAID Vaccine Research Center have isolated and characterized neutralizing antibodies (VRC01, 02, 03, and 07) that bind to the CD4 binding site of HIV-1 envelope glycoprotein gp120. These human monoclonal antibodies can potentially be used as a therapeutic to: (1) treat an HIV infection, (2) decrease and prevent HIV-transmission from mother to infant, and (3) be effectively combined with anti-retroviral drug therapy.

The effectiveness of current influenza vaccines varies by strain and season, in part because influenza viruses continuously evolve to evade human immune responses. While the majority of seasonal influenza infections cause relatively mild symptoms, each year influenza virus infections result in over 500,000 hospitalizations in the United States and Europe. Current standard of care for individuals hospitalized with uncomplicated influenza infection is administration of neuraminidase inhibitors.

A plasmid encodes human CC chemokine receptor CX3CR1/CMKBRL1 as described in DNA Cell Biol. 1995 Aug;14(8):673-80, and developed in the laboratory of Philip M. Murphy at the National Institute of Allergy and Infectious Diseases.